Pharmaceutical

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

The European Commission (EC) has imposed a fine of €462.6m ($502m) on Teva Pharmaceuticals Industries after investigating the company’s practices regarding the standard-of-care multiple sclerosis treatment, Copaxone.

Nov 3, 2024 - 06:00
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
The European Commission (EC) has imposed a fine of €462.6m ($502m) on Teva Pharmaceuticals Industries after investigating the company’s practices regarding the standard-of-care multiple sclerosis treatment, Copaxone.
Read the original article

Tags:

Previous Article

AbbVie and EvolveImmune Therapeutics sign oncology collaboration

Next Article

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA fast tracks Mendus’s acute myeloid leukaemia vaccine vividencel

FDA fast tracks Mendus’s acute myeloid leukaemia vaccin...

Sep 9, 2023

Mammograms are less effective for women with dense breast tissue. Medical experts disagree on what to do about it

Mammograms are less effective for women with dense brea...

Jan 24, 2024

Amgen enlists TScan’s target discovery platform for Crohn’s disease

Amgen enlists TScan’s target discovery platform for Cro...

May 10, 2023